Third-party payors (Medicare, Medicaid, private insurers)
Revenue Exposure
Most customers depend on third-party payor coverage; reimbursement decisions and rates drive product demand and pricing.
Relevance 95·Dependency 90·Confidence 95
Source evidence
“Most of our customers rely on third-party payors, including government programs and private health insurance plans, to cover the cost of the G6, G7, G-7 15 Day, Dexcom One, and Dexcom ONE+.”
CMS DMEPOS Competitive Bidding Program
Regulatory Exposure
CMS competitive bidding extension to CGMs is expected to reduce Medicare reimbursement beginning 2028, directly affecting DexCom pricing and revenue.
Relevance 95·Dependency 85·Confidence 95
Source evidence
“we expect that Medicare reimbursement for our CGM systems will decrease beginning in 2028”
CMS DMEPOS competitive bidding program
Revenue Exposure
Competitive bidding set at 75th percentile of winning bids with monthly rental bundling is expected to decrease Medicare reimbursement for CGM systems beginning 2028.
Relevance 95·Dependency 85·Confidence 95
Source evidence
“the bid process is expected to result in lower Medicare reimbursement for CGM systems”
Mesa, Arizona; Malaysia; San Diego, California
Manufacturing Dependency
Majority of manufacturing concentrated in Mesa, Arizona and Malaysia with limited alternates; disruption would impair production and sales.
Relevance 90·Dependency 85·Confidence 95
Source evidence
“our products are manufactured at certain facilities, with limited alternate facilities”
Medicare beneficiaries
Revenue Exposure
Medicare coverage under the DME benefit, expanded by the April 2023 LCD to all insulin users, is a key driver of US demand.
Relevance 90·Dependency 80·Confidence 95
Source evidence
“Medicare covers the CGM system, which includes both the receiver device and the supplies necessary for the use of the device, under the Durable Medical Equipment, or DME, benefit category”
Polymers for sensor polymeric membranes
Supplier Dependency
Single-source polymers used to synthesize sensor membranes create supply disruption vulnerability for sensor production.
Relevance 85·Dependency 90·Confidence 95
Source evidence
“those single sources include but are not limited to suppliers of application-specific integrated circuits used in our transmitters, seals used for the applicator and certain polymers used to synthesize polymeric membranes for our sensors”
Application-specific integrated circuits (ASICs) for transmitters
Supplier Dependency
Transmitter ASICs are single-sourced, exposing transmitter manufacturing to supply disruption and price fluctuation.
Relevance 85·Dependency 90·Confidence 95
Source evidence
“suppliers of application-specific integrated circuits used in our transmitters”
Single/sole-source ASIC and membrane polymers
Supplier Dependency
Sole/single-source components (transmitter ASIC, biointerface membrane polymers) create supply interruption risk that is hard to replace due to custom design and regulatory requalification.
Relevance 85·Dependency 80·Confidence 90
Source evidence
“we may have difficulty locating and qualifying alternative suppliers for our single-source supplies”
US private third-party payors
Customer Exposure
Coverage and reimbursement from the eight largest private payors, with contracted rates, is an important element of commercial success.
Relevance 85·Dependency 80·Confidence 90
Source evidence
“As of December 31, 2025, the eight largest private third-party payors in the United States, in terms of the number of covered lives, have issued coverage policies for the category of CGM devices”
FDA warning letter
Regulatory Exposure
Failure to respond to the FDA warning letter could lead to product restrictions or market withdrawal, directly affecting revenue.
Relevance 80·Dependency 75·Confidence 90
Source evidence
“If we, our suppliers, or our distributors fail to comply with ongoing regulatory requirements, including responding to the FDA warning letter, or if we have unanticipated problems with our products, the products could be subject to restrictions or withdrawal from the market”
One Big Beautiful Bill Act
Revenue Exposure
Medicaid cuts and stricter eligibility may reduce the number of individuals eligible for coverage who could use DexCom products.
Relevance 80·Dependency 60·Confidence 90
Source evidence
“Decreased federal funding and stricter eligibility requirements may result in more restrictive Medicaid programs at the state level and fewer individuals eligible for coverage, which could have an adverse impact on the number of individuals who seek to use our products and services.”
Direct sales force and distributors/wholesalers
Customer Exposure
Revenue depends on direct sales teams across four regions plus distributor arrangements to reach underrepresented regions and distributor-exclusive payors.
Relevance 75·Dependency 70·Confidence 90
Source evidence
“We have also entered into distribution arrangements to leverage existing distributors (including wholesalers) already engaged in the distribution of drugs, devices and/or products in the diabetes marketplace.”
Third-party payor insured patients
Customer Exposure
Most customers rely on third-party payors (private health insurance) to cover product costs; shifts to patient responsibility create collection and demand risk.
Relevance 70·Dependency 75·Confidence 90
Source evidence
“As most of our customers rely on third-party payors, including private health insurance plans, to cover the cost of our products”
Cybersecurity and data privacy
Legal Exposure
Cyber incidents could compromise confidential data, trigger HIPAA liability, litigation, and government inquiries, disrupting business.
Relevance 70·Dependency 65·Confidence 90
Source evidence
“Cybersecurity risks and cyber incidents could result in the compromise of confidential data or critical data systems and give rise to potential harm to customers, remediation and other expenses, expose us to liability under HIPAA, consumer protection laws, or other common law theories”
April 2023 Medicare Local Coverage Determination
Demand Driver
Expanded Medicare coverage criteria (any-insulin users and problematic hypoglycemia patients) enlarge the eligible patient population and support demand.
Relevance 70·Dependency 55·Confidence 90
Source evidence
“The Local Coverage Determination, or LCD, that CMS released in April 2023 extends Medicare CGM coverage to patients who use any insulin.”
Malaysia
Manufacturing Dependency
Build-out of a manufacturing facility in Malaysia is a disclosed capital investment and asset-value risk if macro conditions deteriorate.
Relevance 60·Dependency 50·Confidence 85
Source evidence
“the build-out of our manufacturing facility in Malaysia and the construction of a new facility in Ireland”
FDA/FTC marketing and advertising regulation
Regulatory Exposure
Direct-to-consumer marketing and social media promotion is subject to FDA, FTC, and HHS-OCR scrutiny; comparative claims risk litigation.
Relevance 55·Dependency 55·Confidence 90
Source evidence
“may subject us to additional scrutiny of our practices of effective communication of risk information, benefits or claims, under the oversight of the FDA, FTC, HHS-OCR, or others.”
Stelo, launched in the US in 2024, is a growth vector requiring expanded distribution capabilities.
Relevance 55·Dependency 40·Confidence 85
Source evidence
“In 2024, we launched Stelo in the United States and are expanding distribution capabilities for its sales.”